Redhill Biopharma Ltd (RDHL)vsUnited Therapeutics Corporation (UTHR)
RDHL
Redhill Biopharma Ltd
$0.89
+1.71%
HEALTHCARE · Cap: $4.49M
UTHR
United Therapeutics Corporation
$541.60
+1.84%
HEALTHCARE · Cap: $23.74B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 33227% more annual revenue ($3.18B vs $9.55M). UTHR leads profitability with a 41.9% profit margin vs -97.5%. UTHR earns a higher WallStSmart Score of 67/100 (B-).
RDHL
Avoid31
out of 100
Grade: F
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for RDHL.
Margin of Safety
+62.9%
Fair Value
$1282.02
Current Price
$541.60
$740.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 58.6% year-over-year
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -17.1% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : RDHL
The strongest argument for RDHL centers on Revenue Growth. Revenue growth of 58.6% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : RDHL
The primary concerns for RDHL are EPS Growth, Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
RDHL profiles as a hypergrowth stock while UTHR is a mature play — different risk/reward profiles.
RDHL carries more volatility with a beta of 4.99 — expect wider price swings.
RDHL is growing revenue faster at 58.6% — sustainability is the question.
UTHR generates stronger free cash flow (173M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 31/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Redhill Biopharma Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company is headquartered in Tel Aviv, Israel.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?